NVAX Stock – US-based biotechnology company Novavax vaccine effective in new strain
A result of trail upon Novavax vaccine for corona virus new strain has reported positively. Let us share that the US-based biotechnology company has developed Novavax vaccine, that has been found effective against Coronavirus’ B1351 variant This new strain was first identified in South Africa.
For your information let us hare that the Novavax vaccine demonstrated an overall efficacy of 49 per cent in the initial analysis. Among healthy adults without HIV, the Novavax vaccine demonstrated efficacy of 60 per cent in the initial analysis, and 55 per cent in the subsequent complete analysis. The initial analysis, published in New England Journal of Medicine, suggested that prior infection with the original Covid-19 strain did not protect against subsequent infection by the variant predominantly circulating in South Africa through 60 days of follow-up.
However, with additional follow-up, the trial indicates that there may be a modest protective effect of prior exposure with the original Covid-19 strain.